MOLECULAR RESPONSE TO THERAPY WITH TYROSINE KINASE INHIBITORS IN PATIENTS WITH BCR-ABL1(+) CHRONIC MYELOID LEUKEMIA PRESENTING WITH AN ISOLATED THROMBOCYTOSIS AT THE ONSET

被引：0
|
作者：
Balatzenko, G. [1 ]
Hrischev, V. [2 ]
Ignatova, K. [2 ]
Stoyanova, Z. [2 ]
Lilova, A. [2 ]
Angelova, S. [1 ]
Ivanova, S. [1 ]
Romanova, M. [1 ]
Ivanova, I. [1 ]
Tsvetkova, G. [3 ]
Hadjiev, E. [3 ]
Madzharova, V. [2 ]
Dikov, T. [2 ]
Spassov, B. [2 ]
Davidkova, Y. [2 ]
Jagurinoski, M. [2 ]
Guenova, M. [2 ]
机构：
[1] Lab Cytogenet & Mol Biol, Sofia, Bulgaria
[2] Natl Specialised Hosp Act Treatment Hematol Dis, Sofia, Bulgaria
[3] Alexandrovska Univ Hosp, Sofia, Bulgaria
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1828
引用
收藏
页码：733 / 733
页数：1
相关论文
共 50 条
  • [21] Discontinuation of tyrosine kinase inhibitors based on BCR-ABL1 monitoring by digital droplet PCR in pediatric chronic myeloid leukemia
    Kim, Yeojae
    Kim, Seongkoo
    Lee, Jong Mi
    Ahn, Ari
    Yoo, Jae Won
    Lee, Jae Wook
    Cho, Bin
    Chung, Nack-Gyun
    Kim, Yonggoo
    Kim, Myungshin
    [J]. FRONTIERS IN PEDIATRICS, 2022, 10
  • [22] Chronic Myeloid Leukemia: Beyond BCR-ABL1
    Zhou, Ting
    Medeiros, L. Jeffrey
    Hu, Shimin
    [J]. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2018, 13 (06) : 435 - 445
  • [23] Chronic Myeloid Leukemia: Beyond BCR-ABL1
    Ting Zhou
    L. Jeffrey Medeiros
    Shimin Hu
    [J]. Current Hematologic Malignancy Reports, 2018, 13 : 435 - 445
  • [24] Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia
    Soverini, Simona
    de Benedittis, Caterina
    Mancini, Manuela
    Martinelli, Giovanni
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S120 - S128
  • [25] Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia
    El Missiry, Mohamed
    Hjorth-Hansen, Henrik
    Richter, Johan
    Olson-Stromberg, Ulla
    Stenke, Leif
    Porkka, Kimmo
    Kreutzman, Anna
    Mustjoki, Satu
    [J]. PLOS ONE, 2017, 12 (01):
  • [26] STUDY OF MUTATIONS IN THE KINASE DOMAIN OF BCR-ABL1 BY NGS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
    Stuckey, Ruth
    Florido, Ortega Yanira
    Rodriguez, Lopez Juan Francisco
    Bilbao, Sieyro Cristina
    Gomez, Casares Maria Teresa
    [J]. HAEMATOLOGICA, 2020, 105 : 239 - 239
  • [27] Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase
    Sasaki, Koji
    Kantarjian, Hagop
    O'Brien, Susan
    Ravandi, Farhad
    Konopleva, Marina
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Wierda, William
    Daver, Naval
    Ferrajoli, Alessandra
    Takahashi, Koichi
    Jain, Preetesh
    Rios, Mary Beth
    Pierce, Sherry
    Jabbour, Elias
    Cortes, Jorge E.
    [J]. CANCER, 2018, 124 (06) : 1160 - 1168
  • [28] Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia
    Lee, Hyewon
    Basso, Igor Novitzky
    Kim, Dennis Dong Hwan
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (05) : 632 - 641
  • [29] BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia
    Roy, Swagata
    Jorgensen, Heather G.
    Roy, Poornima
    El Baky, Mohamed Abed
    Melo, Junia V.
    Strathdee, Gordon
    Holyoake, Tessa L.
    Bartholomew, Chris
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 (04) : 446 - 456
  • [30] Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells
    Tsubaki, Masanobu
    Takeda, Tomoya
    Kino, Toshiki
    Sakai, Kazuko
    Itoh, Tatsuki
    Imano, Motohiro
    Nakayama, Takashi
    Nishio, Kazuto
    Satou, Takao
    Nishida, Shozo
    [J]. ONCOTARGET, 2017, 8 (24) : 38717 - 38730
12345